Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG


EDISON, NJ, Jan. 5, 2022 (GLOBE NEWSWIRE) – Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical-stage biopharmaceutical company focused on the development of artificial intelligence (“AI”) -based therapeutic drugs for the treatment of alcoholic steatohepatitis (“NASH”) and other liver diseases, announced today that the Company’s Medical Director, Dr. Todd Hobbs, will present data from the Phase 2 “AMBITION” study at the NASH-TAG 2022 conference, to be held January 6-8, 2022, in Park City, Utah.

Oral presentation details

Title: Investigation of CRV431 in NASH Patients: Data from the AMBITION Phase 2a Study


Date: Saturday January 8, 2022

Time: 10:30 am MST

Hepion’s AMBITION abstract was one of nine “eminent” abstracts selected for oral presentation at the meeting.

“We are very happy to have been selected to share the positive data from the AMBITION study with clinicians, researchers and regulators at NASH-TAG, one of the most prestigious and clinically-focused NASH meetings. to the world, ”said Dr Hobbs.

A copy of the presentation materials will be available on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.

About Hepion Pharmaceuticals

The Company’s lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease – from trigger events through to the end stage of disease. CRV431 has been shown to reduce hepatic fibrosis and the tumor burden of hepatocellular carcinoma in experimental models of NASH; and has demonstrated antiviral activities against HBV, HCV and HDV through several mechanisms, in non-clinical studies.

Hepion has created a proprietary AI platform, called AI-POWR â„¢, which stands for AArtificial intelligence – Pprecision medicine; ohmicros (including genomics, proteomics, metabolomics, transcriptomics and lipidomics); Waccess to the global database; and Rresponse and clinical results. Hepion intends to use AI-POWR â„¢ to help identify NASH patients who will respond best to CRV431, potentially shortening development times and increasing the delta between the placebo and treatment groups. In addition to using AI-POWR â„¢ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for CRV431 to expand the footprint of the company in the therapeutic space of cyclophilin inhibition.

For more information, please contact:

Stephen kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
[email protected]


Comments are closed.